In the news:
Sanofi pursues sale of France's leading painkiller to US investment fund after controversy - Sanofi joins rivals investing in nuclear cancer treatment - Deal to sell Sanofi unit to US fund deals new blow to French govt - Sanofi deal offers only partial headache relief - France takes stake in Sanofi unit as part of EUR16bn sale to CD&R - Pharmaceutical giant Sanofi looks to sell consumer health unit, sparks political uproar - France warns it could block EUR15.5bn Sanofi consumer health deal - Sanofi in Talks to Sell Controlling Stake in Consumer Health Arm to CD&R - Sanofi in Talks to Sell 50% of Consumer Health Unit to CD&R - Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Sanofi.Com
Save
ShareKey facts
- city: Paris
- country: France
- sector: Health Care
- industry: Pharmaceuticals
- CEO: Paul Hudson
Classified as: organization
Summary
Sanofi.Com is a company. It is located in Paris, France. The company is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Business
Sanofi.Com is one of the companies in France, companies in Pharmaceuticals, companies in Health Care and 3,466,499 companies in our database.
- Assets: 120.6B $
- Debt: 21.3B $
- Employees: 95,442 people
- Free cash flow: 7.3B $
- Market cap: 103.2B $
- Profits: 6.2B $
- Revenues: 42.2B $
Stocks from Sanofi.Com
Explore more on business
Talking Points:
- Sanofi, an innovative global healthcare company
- We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people
- We chase the miracles of science to improve people’s lives. Interactions with this account must comply with the Terms: https://t.co/mXmuqtkblm
- We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible.
- Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Learn more about talking points